Encorafenib: 12 agencies, 2018–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 7.8 years, from 2018 at PBAC (Australia) to 6 May 2026 at NICE (England).
CIPM (Spain) changed its position: not recommended on 30 Sep 2021, recommended by 16 Jul 2025, after a resubmission.
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for encorafenib, 1 submission was never made — an outcome set by the company rather than the assessor.
The file is active: 8 of 28 records date from 2023 or later.
The programme is broad: 8 distinct indication wordings are recorded for encorafenib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 28 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess encorafenib, in 2018; HIRA (South Korea) did not open a file until 3 Aug 2023 — a wide spread of 5.1 years between the earliest and latest system to look at it.
The record arrives in waves: 7 separate years each carry two or more decisions, spread across 8 years in total.
10 of the 12 agencies here assessed encorafenib more than once, AOTMIT (Poland) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
encorafenib has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for encorafenib reads 12 recommended, 4 restricted, 3 deferred to NICE and 3 no benefit, with 6 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 21 Apr 2026 | programu lekowego B.4. „Leczenie chorych na raka jelita grubego (ICD-10: C18-C20) | recommended conditionally | source |
| AWMSG (Wales) | 10 Apr 2026 | In combination with binimetinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF… | excluded, NICE appraised | source |
| SMC (Scotland) | 8 Sep 2025 | In combination with binimetinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation. | not recommended | source |
| CIPM (Spain) | 16 Jul 2025 | Indicaciones terapéuticas autorizadas: Melanoma Encorafenib en combinación con binimetinib está indicado en adultos para… | financed by the SNS · art. 92 a, c | source |
| G-BA (Germany) | 20 Mar 2025 | Braftovi — benefit assessment §35a | added benefit: not proven | source |
23 further decisions for encorafenib, across 12 agencies, are not shown here. They include the most recent record on file, 6 May 2026 from NICE (England); its outcome is in the subscriber dataset. They link to 21 further source documents.
Related molecules
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
- ribociclib — same ATC class L01E — Antineoplastics
Coverage: 28 decisions for encorafenib from 12 agencies, 2018 to 2026. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.